Demographic, clinical and pathologic characteristics.

<p>Demographic, clinical and pathologic characteristics.</p

Kaplan-Meier survival curve comparing progression-free survival estimation between low- and high-expressing E-cadherin, beta-catenin and EGFR groups.

<p>a) Patients with high tumor E-cadherin expression exhibit a higher probability of PFS (59.7% vs. 40.6%, p = 0.04). b) Patients with low expression of beta-catenin trended towards worse PFS (p = 0.057). c) There was no association between EGFR expression and PFS (p = 0.49).</p

Kaplan-Meier survival curve comparing overall survival estimation between low- and high-expressing E-cadherin groups.

<p>a) Patients with high tumor E-cadherin expression exhibit a higher probability of OS (69.6% vs. 44.3%, p = 0.05). b) There was no association between beta-catenin and OS (p = 0.16). c) Patients with high tumor EGFR expression had inferior 5-year overall survival compared with those with low tumor EGFR expression (27.7% vs. 54%, p = 0.029).</p

Multivariable 5-year overall survival (OS) analysis, by Cox regression.

<p>Multivariable 5-year overall survival (OS) analysis, by Cox regression.</p